HOME >> MEDICINE >> NEWS
CellCept associated with reduced incidence of cancer, compared to AZA, following heart transplant

San Francisco, April 23, 2004 - A study presented today at an international transplant meeting showed that heart transplant patients treated with the immunosuppressant CellCept (mycophenolate mofetil) in standard immunosuppressive regimens had a significantly lower risk of developing cancer compared to those receiving non-CellCept-based treatment regimens. Presented at the annual meeting of the International Society for Heart and Lung Transplantation (ISHLT), the study found a 27% lower risk of cancer in CellCept-treated patients. Patients studied were part of the ISHLT Transplant Registry. "Though not derived from randomized controlled trials, these data indicate that the choice of maintenance immunosuppressive regimen may be a modifiable risk factor for the development of malignancy in heart transplant recipients," said James O'Neill, M.D., Fellow in Heart Failure and Cardiac Transplantation, Cleveland Clinic.

Previous research had shown that organ transplant recipients receiving immunosuppressive therapy are three to four times more likely to develop tumors than the general population and have an even greater risk of developing certain rare cancers.

Extensive Examination of Registry Validates CellCept Treatment
The study, Mycophenolate Mofetil and the Risk of Developing Malignancy Following Orthotopic Heart Transplantation (OHT), examined competing risk factors to determine which are associated with malignancy following OHT, and was based on 3,895 patients in the ISHLT Transplant Registry. The study examined survival without malignancy in patients taking standard immunosuppressive regimens (defined as cyclosporine or tacrolimus and azathioprine or CellCept), who underwent OHT between January 1, 1995, and December 31, 1997.

Of these patients, 703 (18%) developed malignancy during the follow-up period through June 30, 2002. The breakdown of malignancy was as follows: skin (47%), post-transplant lymphoproliferative disease (10%),
'"/>

Contact: Julip Cantre
Julio.Cantre@ketchum.com
917-204-0599
Ketchum
23-Apr-2004


Page: 1 2 3

Related medicine news :

1. New data supports CellCepts position as a world leader in solid organ transplantation
2. CellCept(R) registry data demonstrated superior long-term organ transplant outcomes
3. CellCepts cardioprotective profile reinforced
4. Data shows life of kidney transplant lengthened by CellCept
5. Organizational traits associated with quality patient care are essential to home care nursing
6. Depression may explain higher risk of heart attack associated with antidepressants
7. Current daily smoking may be associated with increased risk for suicidal thoughts and attempts
8. Inpatient smoking cessation counseling is associated with early differences in mortality
9. Hypothyroidism associated with reduced breast cancer risk
10. COX-2 inhibitors associated with blood pressure elevation
11. Mothers depression associated with increased risk of childs antisocial behavior

Post Your Comments:
(Date:3/5/2015)... At the 7th Annual Mississippi Addiction Conference ... met today in Jackson, Mississippi to listen to keynote ... numerous respected speakers will be William S. Jacobs, ... pain medications have had in today’s opiate overdose and ... is hard to believe that much of the current ...
(Date:3/5/2015)... University of Western States (UWS), ... has launched a new center of excellence to ... Northwest Center for Lifestyle and Functional Medicine aim ... and conduct research in the areas of lifestyle ... The center will target efforts on the UWS ...
(Date:3/5/2015)... NY (PRWEB) March 05, 2015 Dr. ... Surgeon ( http://www.orthopedicsurgeonnyc.com ) has been named by ... New York Metro area. Dr. Glashow has been selected ... authoritative guide to the top specialty care doctors in ... The prestigious Castle Connolly program, which carefully screens and ...
(Date:3/5/2015)... 05, 2015 Today, Earth Source ... on 100% pollution-free electricity through a partnership with ... As an Arcadia Power Clean Energy Partner, ESO ... Power Partnership requirements, joining national brands such as ... clean energy. Earth Source Organics joins a growing ...
(Date:3/5/2015)... Think it’s tough to get kids to ... them to brush their teeth. That’s a finding from a ... Delta Dental(1) in conjunction with National Parenting Month in March. ... kids to brush their teeth is one of the most ... higher than getting children to eat vegetables regularly (42 percent) ...
Breaking Medicine News(10 mins):Health News:National Addiction Treatment Expert William S. “Bill” Jacobs, Md Speaks At Prestigious 7th Annual Mississippi Addiction Conference 2Health News:National Addiction Treatment Expert William S. “Bill” Jacobs, Md Speaks At Prestigious 7th Annual Mississippi Addiction Conference 3Health News:University of Western States Launches Northwest Center for Lifestyle and Functional Medicine 2Health News:Dr. Jonathan Glashow, NYC Orthopedic Surgeon, Named Top Doctor: New York Metro Area 2Health News:Earth Source Organics to Run on Clean Energy from Arcadia Power 2Health News:Delta Dental Survey Says Parents Have Harder Time Getting Kids to Brush than to Eat Vegetables 2Health News:Delta Dental Survey Says Parents Have Harder Time Getting Kids to Brush than to Eat Vegetables 3
(Date:3/5/2015)... , March 5, 2015  ContraVir Pharmaceuticals, Inc. (NASDAQ: ... the development and commercialization of targeted antiviral therapies, announced ... Annual ROTH Conference, to be held March 8-11, ... James Sapirstein , Chief Executive Officer, ... his live presentation and will be available to participate ...
(Date:3/5/2015)... Calif. , March 5, 2015  Asterias Biotherapeutics, ... the emerging field of regenerative medicine, announced today that ... the nation,s top rehabilitation hospitals for spinal cord injury ... 1/2a clinical trial of AST-OPC1 (oligodendrocyte progenitor cells) in ... spinal cord injury (SCI). The Phase ...
(Date:3/5/2015)... YORK and VANCOUVER, British Columbia ... (CSE: BUX FSE: 20B OTCQB: BMKDF) -- The ultimate ... an assay that is capable of detecting tumors before ... forty years, the development of such an assay has ... in academia and industry. Although many breakthrough diagnostics have ...
Breaking Medicine Technology:ContraVir to Present at 27th Annual ROTH Conference 2Asterias Biotherapeutics Initiates Patient Enrollment for Phase 1/2a Clinical Trial of AST-OPC1 in Newly Injured People with Complete Cervical Spinal Cord Injury 2Asterias Biotherapeutics Initiates Patient Enrollment for Phase 1/2a Clinical Trial of AST-OPC1 in Newly Injured People with Complete Cervical Spinal Cord Injury 3Asterias Biotherapeutics Initiates Patient Enrollment for Phase 1/2a Clinical Trial of AST-OPC1 in Newly Injured People with Complete Cervical Spinal Cord Injury 4New Cancer Diagnostic Primed to Change the Industry 2New Cancer Diagnostic Primed to Change the Industry 3New Cancer Diagnostic Primed to Change the Industry 4
Cached News: